Ligand Pharmaceuticals (LGNDZ) Long-Term Investments (2016 - 2025)
Ligand Pharmaceuticals (LGNDZ) has disclosed Long-Term Investments for 16 consecutive years, with $121.5 million as the latest value for Q4 2025.
- Quarterly Long-Term Investments rose 1047.6% to $121.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $121.5 million through Dec 2025, up 1047.6% year-over-year, with the annual reading at $121.5 million for FY2025, 1047.6% up from the prior year.
- Long-Term Investments hit $121.5 million in Q4 2025 for Ligand Pharmaceuticals, up from $42.0 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $375.0 million in Q1 2021 to a low of $10.5 million in Q1 2024.
- Historically, Long-Term Investments has averaged $195.0 million across 5 years, with a median of $121.5 million in 2025.
- Biggest five-year swings in Long-Term Investments: plummeted 97.21% in 2024 and later soared 1047.6% in 2025.
- Year by year, Long-Term Investments stood at $375.0 million in 2021, then changed by 0.0% to $375.0 million in 2022, then crashed by 96.64% to $12.6 million in 2023, then decreased by 15.97% to $10.6 million in 2024, then skyrocketed by 1047.6% to $121.5 million in 2025.
- Business Quant data shows Long-Term Investments for LGNDZ at $121.5 million in Q4 2025, $42.0 million in Q3 2025, and $62.1 million in Q2 2025.